Acute-phase response in bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of Zoledronate or Ibandronate

Primary tabs

NEWS
Acute-phase response in bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of Zoledronate or Ibandronate

Acute phase response is a group of systemic and metabolic processes that happens in response to the onset of infection, trauma, inflammatory processes and some malignant conditions. The most important change is a dramatic increase of acute phase proteins in the serum, particularly C-reactive protein (CRP) and acute-phase response (APR) might be linked with first intravenous (IV) dose of bisphosphonates such as Zoledronate (ZOL) and Ibandronate (IBN) in bisphosphonate-naïve women with postmenopausal osteoporosis.

A study was performed to analyze the characteristics of APR (rates, severity, signs, and symptoms), without any preventive measure, after a first IV dose of ZOL or IBN in patients naïve or who had previous BP exposure in a real-world clinical setting.

The study was an open-labeled prospective exploratory study that included 725 consecutive postmenopausal women with osteoporosis, divided into the cohort (411 ZOL and 314 IBN), treated with either IV ZOL or IBN at the Department of Osteoporosis of the University Hospital of Berne, Switzerland. Prior use of oral or IV BP was less frequent in the ZOL group (61.8 vs. 71.7%, p=0.005).

Results of this study estimated that one or more signs or symptoms of APR were noticed in 301 women (41.5%), with rates for ZOL (47.7 %) and IBN (33.4%), (p<0.001). In the subgroup of BP-naïve patients, APR rates for ZOL (55.6%) and IBN (32.4%), (p<0.001). The presence of main APR clinical sign indicated post-dose myalgia or arthralgia (68.1%). Those with previous BP exposure were at predicted risk of both APR and lower serum 25-hydroxy vitamin D (25(OH)D) levels.

Therefore, it was estimated that in a real-world setting, APR rates with the administration of ZOL and IBN might be higher as compared to rates reported in randomized controlled trials and might vary by the compound, prior BP exposure and serum 25(OH)D levels.

Source:

Osteoporosis International

Link to the source:

https://link.springer.com/article/10.1007%2Fs00198-017-3992-5

The original title of the article:

Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate

Authors:

A.W. Popp, R. Senn, et al.

SearchTags: 
Osteoporosis, Zoledronate, Ibandronate
Log in or register to post comments